title: Impact of adjuvant chemotherapy for gliomatosis cerebri.
abstract: BACKGROUND
  Gliomatosis cerebri (GC) is characterized by a diffuse infiltration of tumor cells throughout CNS, however, few details are available about the chemotherapeutic effect on GC. The aim of this study was to investigate its clinical course and to determine the efficacy of chemotherapy for GC.
  
  
  METHODS
  Between Jan. 1999 and Dec. 2004, 37 GC patients were diagnosed by biopsy and treated with radiotherapy in a single institution. To determine the efficacy of chemotherapy for GC, we retrospectively reviewed their clinical courses. The study cohort was divided into 2 groups, those with and without receiving post-radiotherapy adjuvant chemotherapy such as temozolomide or nitrosourea-based chemotherapy.
  
  
  RESULTS
  Nineteen patients with adjuvant chemotherapy were assigned to the chemotreatment group and 18 with radiotherapy alone were assigned to the control group. Mean survival for chemotreatment group and control group were 24.2 and 13.1 months, respectively (p = 0.045). Time to progression for these groups were 16.0 and 6.0 months, respectively (p = 0.007). Overall review of the clinical course of patients with GC provided that early appearance of new contrast-enhancing lesions within 6 months from the initial diagnosis and higher histological grade were closely associated with poor survival (p < 0.001 and p = 0.008).
  
  
  CONCLUSIONS
  Adjuvant chemotherapy following radiotherapy could prolong the survival in patients with GC. In addition, newly developed contrast-enhanced lesions on the follow-up MR images indicate the progression of GC.
authors: Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors: Doo-Sik
authors: DS
authors: Kong
authors: Sung Tae
authors: ST
authors: Kim
authors: Jung-Il
authors: JI
authors: Lee
authors: Yeon-Lim
authors: YL
authors: Suh
authors: Do Hoon
authors: DH
authors: Lim
authors: Won Seog
authors: WS
authors: Kim
authors: Ki-Hoon
authors: KH
authors: Kwon
authors: Kwan
authors: K
authors: Park
authors: Jong Hyun
authors: JH
authors: Kim
authors: Do-Hyun
authors: DH
authors: Nam
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000150:complications* / Q000473:pathology / Q000532:radiotherapy*; D002330:Carmustine / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D002648:Child; D015331:Cohort Studies; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018302:Neoplasms, Neuroepithelial / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D009381:Neoplasms, Radiation-Induced / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D011344:Procarbazine / Q000008:administration & dosage; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D000077204:Temozolomide; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine; D003606:Dacarbazine; D002330:Carmustine; D000077204:Temozolomide